One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.On November 14, New York City-based Commodore Capital disclosed a new position in Amylyx Pharmaceuticals (AMLX +2.76%), acquiring nearly 4.1 million shares valued at approximately $55 million, according to a recent SEC filing.What HappenedAccording to a filing with the U.S. Securities and Exchange Commission dated November 14, Commodore Capital LP disclosed a new stake in Amylyx Pharmaceuticals (AMLX +2.76%). ...